Efficacy and safety of nemolizumab versus placebo for the treatment of atopic dermatitis
Year: 2024
Type: dissertation
Study design: Systematic Review
Abstract: Eczema is one of the most common skin diseases and affecting approximately 10% of the population. Eczema which is now known as dermatitis, is due to an inflammatory process in the upper skin layers and comes in different variants. Emollients are the basis for treating dermatitis and it is to protect and strengthen the skin's barrier function. In addition to emollients, local corticosteroids are used, which have an antipruritic and anti-inflammatory effect. Nemolizumab is a humanized monoclonal against the interleukin-31 receptor that should reduce itching and skin inflammation. The purpose of this work was to investigate how effective and safe treatment with nemolizumab is in atopic dermatitis. A literature search took place in the database PubMed based on the publication years 2014–2024. Inclusion criteria were phase 2 and phase 3 studies, patients with atopic dermatitis at the age of 13 years or older, follow-up time of 12–48 weeks and that the studies looked at the treatment effect of pruritus. Based on these criteria, six RCT studies qualified for inclusion. The results from these six showed nemolizumab had a more effective antipruritic effect compared to placebo treatment. The six studies presented their results through VAS scores, EASI scores, ISI scores, DLQI scores, IGA, POEM and PP-NRS scores. The studies presented percentage reductions in VAS scores already during week one. The rate of serious side effects was relatively low. The conclusion of this work is that nemolizumab is effective and safe as a treatment for atopic dermatitis. However, several longer studies need to be done to show that the effect lasts over a longer period and not just for 16 weeks.
Source: DiVA (Linnaeus University)
Author: Garp, Lisa
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7047092293
